Gamida Cell Reports First Patient Dosing in P-I/II Study of GDA-201 for the Treatment of Follicular and Diffuse Large B Cell Lymphoma
Shots:
- The 1st patient has been dosed in the P-I/II study in which the P-I dose escalation study evaluates the safety of GDA-201 in patients with FL, DLBCL/HGBL, MZL & MCL whereas the P-II expansion study evaluates the safety & efficacy of GDA-201 in patients (n=63) divided into two groups with either FL or DLBCL
- Earlier, the results from an investor-sponsored P-I/II study evaluating GDA-201 + rituximab in patients (n=19) with NHL showed a complete (n=13) & partial response (n=1) in patients along with an OR of 74%, CRR of 68%, mDoR of 16mos. & an OS at 2yrs of 78%
- GDA-201 is an innate NK cell immunotherapy developed by using Gamida’s NAM-enabled cell expansion technology for the treatment of hematologic & solid tumors
Ref: Businesswire | Image: Gamida Cell
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
